Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk)

作者：Vogiatzoglou Anna; Mulligan Angela A; Bhaniani Amit; Lentjes Marleen A H; McTaggart Alison; Luben Robert N; Heiss Christian; Kelm Matte; Merx Marc W; Spencer Jeremy Re; Schroeter Hagen; Khaw Kay Tee; Kuhnle Gunter G C^*

来源：Free Radical Biology and Medicine, 2015, 84: 1-10.

DOI：10.1016/j.freeradbiomed.2015.03.005

• Flavan-3-ols
• Cardio-vastular diseases
• Nutritional epidemiology
• EPIC Norfolk

Dietary intervention studies suggest that flavan-3-ol intake can improve vascular function and reduce the risk of cardiovascular diseases (CVD). However, results from prospective studies failed to show a consistent beneficial effect. Associations between flavan-3-ol intake and CVD risk in the Norfolk arm of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) were investigated. Data were available from 24,885 (11,252 men; 13,633 women) participants, recruited between 1993 and 1997 into the EPIC-Norfolk study. Flavan-3-ol intake was assessed using 7-day food diaries and the FLAVIOLA Flavanol Food Composition database. Missing data for plasma cholesterol and vitamin C were imputed using multiple imputation. Associations between flavan-3-ol intake and blood pressure at baseline were determined using linear regression models. Associations with CVD risk were estimated using Cox regression analyses. Median intake of total flavan-3-ols was 1034 mg/d (range: 0-8531 mg/d) for men and 970 mg/d (0-6695 mg/d) for women, median intake of flavan-3-ol monomers was 233 mg/d (0-3248 mg/d) for men and 217 (0-2712 mg/d) for women. There were no consistent associations between flavan-3-ol monomer intake and baseline systolic and diastolic blood pressure (BP). After 286,147 person-years of follow-up, there were 8463 cardiovascular events and 1987 CVD related deaths; no consistent association between flavan-3-ol intake and CVD risk (HR 0.93, 95% CI: 0.87; 1.00; Q1 vs Q5) or mortality was observed (HR 0.93, 95% CI: 0.84; 1.04). Flavan-3-ol intake in EPIC-Norfolk is not sufficient to achieve a statistically significant reduction in CVD risk.

• 出版日期2015-7